You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 27, 2024

Details for Patent: 10,154,990


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,154,990 protect, and when does it expire?

Patent 10,154,990 protects OFEV and is included in one NDA.

Protection for OFEV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-four patent family members in thirty-three countries.

Summary for Patent: 10,154,990
Title:Medicaments for the treatment or prevention of fibrotic diseases
Abstract: The present invention relates to the use of indolinones of general formula ##STR00001## substituted in the 6 position, wherein R.sub.1 to R.sub.5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
Inventor(s): Park; John Edward (Warthausen, DE), Roth; Gerald Juergen (Biberach, DE), Heckel; Armin (Biberach, DE), Chaudhary; Nveed (Southampton, GB), Brandl; Trixi (Allschwil, CH), Dahmann; Georg (Warthausen-Birkenhard, DE), Grauert; Matthias (Biberach an der Riss, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:14/982,179
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,154,990
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 10,154,990

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-002 Oct 15, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,154,990

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04030770Dec 24, 2004

International Family Members for US Patent 10,154,990

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 052177 ⤷  Try a Trial
Australia 2005318126 ⤷  Try a Trial
Belgium 2015C038 ⤷  Try a Trial
Brazil PI0519370 ⤷  Try a Trial
Canada 2591083 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.